Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.

BACKGROUND: Osteoprotegerin (OPG) is a tumour and/or bone derived factor that may protect tumour cells from apoptosis. In this study, we have measured serum OPG levels in untreated prostate cancer patients with advanced prostate cancer compared to patients with organ confined disease and in treated...

Bibliografiset tiedot
Päätekijät:	Eaton, C, Wells, J, Holen, I, Croucher, P, Hamdy, F
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	2004

Samankaltaisia teoksia

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
Tekijä: Eaton, C, et al.
Julkaistu: (2004)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
Tekijä: Holen, I, et al.
Julkaistu: (2002)

Role of osteoprotegerin (OPG) in cancer.
Tekijä: Holen, I, et al.
Julkaistu: (2006)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
Tekijä: Holen, I, et al.
Julkaistu: (2002)

The role of osteoprotegerin in breast and prostate cancer
Tekijä: Holen, I, et al.
Julkaistu: (2002)

OPG is a survival factor for breast- and prostate cancer cells in vitro
Tekijä: Holen, I, et al.
Julkaistu: (2002)

Polymorphisms within the osteoprotegerin (OPG) gene are associated with both serum OPG levels and bone mineral density.
Tekijä: Miles, L, et al.
Julkaistu: (2004)

Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome
Tekijä: Gamal B Mohamed, et al.
Julkaistu: (2011-01-01)

Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
Tekijä: Holen Ingunn, et al.
Julkaistu: (2009-07-01)

Role of Osteoprotegerin (OPG) in Bone Marrow Adipogenesis
Tekijä: Lili Zhang, et al.
Julkaistu: (2016-11-01)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
Tekijä: Riham Eid, et al.
Julkaistu: (2023-06-01)

Significant Inverse Correlation of Serum Levels of Osteoprotegerin (OPG) and Transferrin Saturation in Thalassemia Dependent Transfusion (TDT) Patients
Tekijä: Indra Wijaya, et al.
Julkaistu: (2024-01-01)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
Tekijä: Croucher, P, et al.
Julkaistu: (2000)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
Tekijä: Shipman, C, et al.
Julkaistu: (2002)

Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19
Tekijä: Siamak Kazemi-Sufi, et al.
Julkaistu: (2024-09-01)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
Tekijä: Shipman, C, et al.
Julkaistu: (2000)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
Tekijä: Shipman, C, et al.
Julkaistu: (2002)

Endogenous osteoprotegerin (OPG) represses ERα and promotes stemness and chemoresistance in breast cancer cells
Tekijä: Noura N. Alraouji, et al.
Julkaistu: (2024-08-01)

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
Tekijä: Chan Kai-Ming, et al.
Julkaistu: (2011-07-01)

Osteoprotegerin (OPG): A potential biomarker for adverse cardiovascular events in stable coronary artery disease
Tekijä: Syed Muhammad Muneeb Akhtar, et al.
Julkaistu: (2024-07-01)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
Tekijä: Waterman, E, et al.
Julkaistu: (2007)

Changes of serum osteoprotegerin level in recurrent urolithiasis
Tekijä: A. V. Savilov, et al.
Julkaistu: (2023-10-01)

Analysis of periodontal parameteres and salivary levels of Receptor Activator of NF- κβ Ligand (RANKL) and Osteoprotegerin (OPG) in obese periodontitis patients
Tekijä: Cheema, Raheem Ramzan
Julkaistu: (2021)

Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts
Tekijä: Yao Jing, et al.
Julkaistu: (2011-03-01)

Can androgen receptor levels in the prostate predict non-organ-confined prostate cancer?
Tekijä: Hamdy, F
Julkaistu: (2005)

Osteoprotegerin and the development of myeloma bone disease
Tekijä: Croucher, P, et al.
Julkaistu: (2004)

Serum levels of OPG, RANKL and RANKL/OPG ratios in newly-diagnosed patients with multiple myeloma. Clinical correlations
Tekijä: Veselina Goranova-Marinova, et al.
Julkaistu: (2007-07-01)

Enhancing androgen ablation response in metastatic hormone-sensitive prostate cancer: the benefits of transurethral resection of the prostate
Tekijä: Yan Zhao, et al.
Julkaistu: (2023-07-01)

Rapid Androgen-Responsive Proteome Is Involved in Prostate Cancer Progression
Tekijä: Jong-Kwang Kim, et al.
Julkaistu: (2021-12-01)

Osteoprotegerin, sclerostin, and osteocalcin serum levels in thyroid disorder patients
Tekijä: F. F. Rija, et al.
Julkaistu: (2021-10-01)

Serum Osteoprotegerin Levels and the Vascular Reactivity Index in Patients with Hypertension
Tekijä: Yen-Liang Chen, et al.
Julkaistu: (2023-10-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
Tekijä: Yosra Azizpour, et al.
Julkaistu: (2020-01-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
Tekijä: Yosra Azizpour, et al.
Julkaistu: (2020-01-01)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Tekijä: Croucher, P, et al.
Julkaistu: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
Tekijä: Croucher, P, et al.
Julkaistu: (2001)

The Role of procollagen type 1 amino-terminal propertied (P1NP) Cytochrome P450 (CYPs) and Osteoprotegerin (OPG) as Potential Bone function markers in Prostate Cancer Bone Metastasis
Tekijä: Yousif Pshtiwan A., et al.
Julkaistu: (2023-01-01)

Serum level of osteoprotegerin in patients with Parkinson’s disease: a preliminary study
Tekijä: Marta Piaścik-Gromada, et al.
Julkaistu: (2024-03-01)

Determinant Factors and Added Value of Osteoprotegerin (OPG) to Detect Carotid Intima-Media Thickness (CIMT) in Type 2 Diabetes Mellitus Patient
Tekijä: Shirly Elisa Tedjasaputra, et al.
Julkaistu: (2018-06-01)

Osteoprotegerin (OPG) Upregulation Activates Breast Stromal Fibroblasts and Enhances Their Pro-Carcinogenic Effects through the STAT3/IL-6 Signaling
Tekijä: Huda K. Al-Nasrallah, et al.
Julkaistu: (2022-10-01)

Duchenne muscular dystrophy: RANK/RANKL/OPG (receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin) system and glucocorticoids
Tekijä: Salvador Atilano-Miguel, et al.
Julkaistu: (2022-01-01)